Clinical trials located in

Hradec Králové

Hradec Králové city is located in Czechia. Currently, 20 clinical trials are being conducted in this city.

Hradec Králové, located at the confluence of the Elbe and Orlice rivers in Czechia, is known as the “Salon of the Republic” due to its significant architectural heritage. This city, with origins dating back to the 1220s, was once a queen’s dowry town, reflecting its name which translates to “Castle of the Queen.” It boasts a unique blend of historical and modern architecture, including the work of Jan Kotěra, a pioneer of modern Czech architecture. Hradec Králové is also renowned for hosting one of the oldest and largest music festivals in the country, the Rock for People festival, attracting music enthusiasts from across the globe.

  • CT-EU-00120106

    Study of Elafibranor in the treatment of adult patients with Primary Biliary Cholangitis (PBC)

    The clinical trial is aimed at adult patients with confirmed primary cholangitis (PBC). Patients with this condition have an inadequate response or intolerance to ursodeoxycholic acid (UDCA), a drug used to treat PBC.

    Primary cholangitis is a disease that slowly progresses and leads to damage to the bile ducts in the liver. This causes a build-up of bile acids, which further damages the liver. As the disease progresses, scarring of the liver may develop (cirrhosis). PBC is also associated with numerous symptoms, such as itching and fatigue, and may lead to the need for a liver transplant.

    The study evaluates the effectiveness and safety of a drug called elafibranor at a dose of 80 mg daily. The study will compare elafibranor with a placebo, an inactive substance administered for control purposes. The main goal of the study is to test the effectiveness of elafibranor. The safety of long-term use of this medicine and its effect on symptoms such as itching and fatigue will also be checked.

    • Elafibranor
  • Study on the safety and effectiveness of Setanaxib for Alport Syndrome patients

    The purpose of this study is to learn about the safety and tolerability of a drug called setanaxib in patients with Alport syndrome, when added to their standard of care treatment. The study will compare how safe setanaxib is when compared to a placebo. Participants will be asked about any side effects they experience at each study visit. Additionally, tests in blood, urine, and other examinations will be used to assess the safety of setanaxib. The study will also measure how well setanaxib works in comparison to a placebo by measuring urine protein and certain markers in the blood and urine. The concentration of setanaxib in the blood will also be measured throughout the course of the study.

    This is a Phase 2a, randomized, double-blind, placebo-controlled study. This means that participants will be randomly assigned to receive either setanaxib or a placebo, and neither the participants nor the researchers will know who is receiving which treatment.

    • placebo
    • Setanaxib
  • To evaluate a combination of 3 different drugs versus 2 other drugs in the treatment of patients with melanoma

    This study compares two different approaches to treating advanced melanoma, a type of skin cancer that has spread to other parts of the body. This study is specifically aimed at patients with a gene mutation called BRAF who have previously received treatment with drugs such as nivolumab or pembrolizumab.

    One therapeutic approach involves taking three study drugs: pembrolizumab administered intravenously every 3 weeks, along with encorafenib and binimetinib taken orally daily at home. The second approach involves taking two study drugs: ipilimumab and nivolumab administered intravenously every 3 weeks for the first 4 doses, followed by nivolumab alone every 4 weeks. Both treatments will last for approximately 2 years, but there is no time limit for treatment with encorafenib and binimetinib.

    The research team will closely monitor the patients’ health during regular clinic visits to see how they are responding to treatment. The main goal is to determine which treatment method is more effective in shrinking or eliminating melanoma tumors.

    • Nivolumab
    • Ipilimumab
    • Binimetinib
    • Encorafenib
    • Pembrolizumab
  • Study on combining two drugs – Fianlimab and Cemiplimab in patients with previously untreated melanoma

    This study examines two drugs, fianlimab and cemiplimab, given together for the treatment of melanoma. The main goal is to see how effective this drug combination is in treating melanoma compared with pembrolizumab, which is already approved for the treatment of melanoma in adults. The study will also look at whether there are any differences in the effects of these experimental drugs in adolescents and adults.

    Scientists also want to learn about other key issues: what side effects may occur from taking these experimental drugs, how much of the drugs enter the bloodstream over time, and whether the body produces antibodies to the drugs that could make them less effective or cause side effects. They will also check whether taking medications improves patients’ quality of life. Fianlimab and cemiplimab will be administered by intravenous infusion, and pembrolizumab will be administered by intravenous infusion.

    • placebo
    • Fianlimab
    • Cemiplimab
    • Pembrolizumab
  • Examining capivasertib and docetaxel in advanced prostate cancer

    This trial is testing a new potential treatment for a type of advanced prostate cancer. The study will compare two combinations: one with Capivasertib and another called Docetaxel, compared with placebo (a dummy tablet with no medical effect) and Docetaxel. In addition, each study participant will receive steroid treatment and another therapy called androgen deprivation therapy. The main goal of this study is to demonstrate whether Capivasertib + Docetaxel extends patients’ lives more than placebo + Docetaxel. They will also be monitored for the time it takes for the cancer to show signs of growth again, for the pain to increase or for urinary symptoms to worsen.

    • Capivasertib
    • Docetaxel
  • Study on new combination therapy for aggressive lymphoma

    This study is about a less common but severe form of cancer known as Diffuse Large B-Cell Lymphoma (DLBCL). It is testing if a new medication called epcoritamab, given with a mix of other commonly used cancer medicines, can help control the disease better. These other medicines include rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone, which are often collectively referred to as R-CHOP. The study includes about 900 adults from around the world who have recently been diagnosed with this type of lymphoma. They will be split into two groups. One group will get epcoritamab with R-CHOP and then continue with epcoritamab. The other group will get R-CHOP followed by rituximab. Doctors will carefully watch for changes in the disease and for any side effects. There will be many checks on health, including medical exams, blood tests, questionnaires, and monitoring of any side effects.

    • Prednisone
    • Vincristine
    • Doxorubicin
    • Epcoritamab
    • Cyclophosphamide
    • Rituximab
  • Testing a new combination therapy with acalabrutinib for a specific type of lymphoma

    This clinical trial is investigating a new combination therapy for diffuse large B-cell lymphoma, a type of lymphoma. The treatment combines Acalabrutinib, a targeted therapy drug, with R-CHOP, a chemotherapy mix consisting of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone, a standard chemotherapy regimen. The aim of the study is to evaluate the safety and effectiveness of this combination in improving patient outcomes. It focuses on patients who have not been previously treated for lymphoma. The study aims to find better treatment strategies for this particular type of lymphoma.

    • Prednisone
    • Vincristine
    • Doxorubicin
    • Acalabrutinib
    • Cyclophosphamide
    • Rituximab
  • Study on the efficacy of pirtobrutinib for mantle cell lymphoma

    This clinical trial is designed for patients diagnosed with mantle cell lymphoma (MCL), a type of blood cancer. The primary objective of the study is to assess the efficacy of a new drug called pirtobrutinib in comparison to other similar drugs that have received approval from the U.S. Food and Drug Administration (FDA). Participants may be involved in the study for a duration of two years or more, contingent on their condition not worsening. The trial will categorize patients into two groups: one receiving pirtobrutinib, and the other receiving either ibrutinib, acalabrutinib, or zanubrutinib, which are existing FDA-approved drugs for this condition. Throughout the study, the participants’ health condition, symptoms, and any side effects will be closely monitored. Additionally, the effectiveness of the treatments will be measured by evaluating the eventual survival rates of the patients.

    • Pirtobrutinib/LOXO-305
    • Zanubrutinib
    • Ibrutinib
    • Acalabrutinib
  • Exploring treatment options for newly diagnosed Multiple Myeloma

    This clinical trial investigates two treatment paths for newly diagnosed multiple myeloma patients who are not planned for stem cell transplant initially. The first group receives a combination of bortezomib, lenalidomide, and dexamethasone (VRd) followed by cilta-cel, an innovative therapy. The second group receives VRd followed by continued treatment with lenalidomide and dexamethasone (Rd). The study evaluates the effectiveness of these treatments by monitoring disease progression, treatment response, and patient survival rates. It also assesses the safety and side effects of the treatments, aiming to improve the quality of life and outcomes for patients with multiple myeloma. The trial’s objective is to provide valuable data on the potential benefits of integrating cilta-cel in the treatment regimen, compared to the more traditional approach, offering insights for better management of this challenging cancer.

    • Cilta-cel
    • Fludarabine
    • Lenalidomide
    • Dexamethasone
    • Cyclophosphamide
    • Bortezomib
  • Testing orforglipron for obesity & type 2 diabetes

    A drug called Orforglipron is being tested. This study is for adults who are overweight or have a disease called type 2 diabetes. The purpose of this study is to see if this medicine can safely help people lose weight. Some patients will receive orforglipron once a day, the rest will receive a placebo. All patients will be monitored to see how their weight changes. The study will last 77 weeks.

    • Orforglipron
  • Comparing favezelimab/pembrolizumab combo with standard chemotherapy for Hodgkin lymphoma

    This study is investigating a treatment for PD-(L)1-refractory, relapsed, or refractory classical Hodgkin lymphoma, a type of blood cancer. Researchers are evaluating a new drug combination known as MK-4280A (favezelimab/pembrolizumab) alongside standard drugs typically used for this condition (bendamustine or gemcitabine). The aim is to determine if MK-4280A is superior to the standard drugs in extending patients’ lifespan and slowing down disease progression. Additionally, scientists will assess the safety and tolerability of MK-4280A during the study, noting any potential side effects of the drug.

    • Favezelimab
    • Pembrolizumab
    • Bendamustine
    • Gemcitabine
  • Testing the effect of the new drug on Crohn’s Disease

    This study is exploring a new medication for Crohn’s disease, an ailment of the gut. The medication, known as BI 706321, is given alongside another medication called Ustekinumab that is already used to treat Crohn’s. The trial is conducted to see if this combination helps to manage the disease better. Participants will be split into two groups. One group will be given the new medication and the other will receive a placebo, alongside Ustekinumab. Participating in this study will last for 1 year. During this time, participants will have about 13 visits to the clinic. Some visits will involve a colonoscopy where doctors look at the intestine’s condition. Their findings will help doctors understand if the new treatment is working.

    • BI 706321- new potential medication for Crohn’s disease
    • ustekinumab
  • Comparing the effectiveness of two treatments for severe nasal polyps and asthma

    This study is looking at two medications, called Dupilumab and Omalizumab, to see how well they work in people who have severe nose and sinus problems alongside asthma. The main goal is to see if Dupilumab is better at shrinking nasal polyps (small growths in the nose) and improving the sense of smell. Other goals include seeing if Dupilumab can improve symptoms, lung function, and overall health-related quality of life better than Omalizumab. The study also aims to understand how these drugs affect the severity of the disease and asthma control, and their safety. To assess all these, doctors will use various tests, like measuring the size of nasal polyps, testing the ability to smell, and how well one’s lungs are working. Participants in the study will be involved for 38 weeks.

    • Dupilumab
    • Omalizumab
  • Comparing treatments in multiple myeloma: talquetamab in combination with other medication

    This study aims to explore the combined effects of talquetamab, daratumumab, pomalidomide, and dexamethasone for treating relapsed or refractory multiple myeloma. One group of patients will receive talquetamab subcutaneous in combination with daratumumab and pomalidomide. The second group will receive talquetamab subcutaneous in combination with daratumumab. The patients of the third group will be treated with daratumumab subcutaneous in combination with pomalidomide and dexamethasone. The research is divided into three phases: screening, treatment, and post-treatment follow-up. The study will assess efficacy, safety, and monitoring various health indicators at specific time points. The results of this combination therapy will be compared to choose the safest and the most effective treatment. The overall duration of the study is expected to be up to 6 years and 6 months.

    • Pomalidomide
    • Talquetamab
    • Dexamethasone
    • Daratumumab
  • Study of etrasimod in treating intense ulcerative colitis

    This study is a follow-up to previous research for the treatment of people with moderate to serious ulcerative colitis (UC). UC is a condition that inflames the large intestine and causes sores on the inside. The study will monitor the effects and safety of a medicine called etrasimod. This research is for people who have been part of past research trials and wish to continue treatment. Doctors will track a few things like side effects and how the medicine affects the disease in ways they have designed.

    • Etrasimod
  • Long-term study on the effectiveness of mirikizumab for Crohn’s Disease

    This research study is about a long-term test of a medicine called Mirikizumab for people who have Crohn’s disease. The main aim of this study is to know if the medicine is effective and safe for those people eventually. The effect of the medicine will be checked using different tests and scores like the Simple Endoscopic Score for Crohn’s Disease, the Crohn’s Disease Activity Index, and patient-reported outcomes. Researchers will also be checking changes in certain markers in the blood and stool that can show inflammation.

    • Mirikizumab
  • Monitoring the long-term safety of Nivolumab for cancer survivors

    This study is designed to understand the long-term effects of a medicine called Nivolumab in patients who have fought against various forms of cancer. In this study, the focus is on closely examining the long-term efficiency and safety of Nivolumab. Participants in the investigation encompass both current and past users of Nivolumab.

    • Nivolumab
  • Study of evorpacept in patients with advanced HER2+ gastric cancer

    This study will investigate the drug evorpacept (ALX148). The clinical trial consists of two phases and includes patients with advanced stomach or gastroesophageal junction (GEJ) cancer showing excessive HER2 receptor expression. The study focuses on patients whose disease did not respond to prior HER2-directed therapy and chemotherapy containing fluoropyrimidine or platinum. Patients participating in the study will be closely monitored to see how well the cancer responds to the treatment and to track any side effects they might experience. By looking at these results, researchers hope to find out if this new combination can offer a more effective treatment option for patients with this type of advanced gastric cancer, potentially leading to better management of the disease and improved survival rates.

    • Evorpacept/ALX148
    • Ramucirumab
    • Trastuzumab
    • Paclitaxel
  • Study on risk reduction of heart complications with Milvexian

    This study involves a drug called milvexian, which is being tested for people who have recently experienced a heart-related episode, like a heart attack or stroke (acute coronary syndrome). Half of the participants will receive milvexian, and the other half will get a placebo. The study’s main aim is to show that milvexian can help reduce the chance of major heart-related problems happening again. These problems include things like heart failure, another heart attack, or an ischemic stroke.

    • Milvexian

See more clinical trials in other cities in Czechia:

.